Tag : Everolimus

Cardiology

Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent.

Newsemia
Related Articles Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable...
Latest News

Synthetic mRNA nanoparticles restore tumor suppressor gene, make cancer cells susceptible to drugs

Newsemia
In preclinical experiments, investigators restored p53 using synthetic mRNA nanoparticles, making lung and liver cancer cells susceptible to available cancer drugs. Source link...
Latest News

IDEAL LM study: Biodegradable polymer everolimus-eluting stent is safe, effective for patients undergoing PCI

Newsemia
New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe...
Latest News

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Newsemia
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding...
Latest News

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis

Newsemia
Mujica-Mota, R; Varley-Campbell, J; Tikhonova, I; Cooper, C; Griffin, E; Haasova, M; Peters, J; … Hoyle, M; + view all Mujica-Mota, R; Varley-Campbell, J; Tikhonova,...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy